CV changes associated with TKIs in patients with CML and provisional recommendations for CV treatment
| TKI . | CV changes . |
|---|---|
| Dasatinib | Pleural/pericardial effusion |
| Pulmonary hypertension | |
| Vascular events+/− | |
| Nilotinib | QT prolongation |
| Hyperglycemia | |
| Hypertension+/− | |
| Hyperlipidemia+/− | |
| Vascular events | |
| Ponatinib | Hypertension |
| Vascular events |
| TKI . | CV changes . |
|---|---|
| Dasatinib | Pleural/pericardial effusion |
| Pulmonary hypertension | |
| Vascular events+/− | |
| Nilotinib | QT prolongation |
| Hyperglycemia | |
| Hypertension+/− | |
| Hyperlipidemia+/− | |
| Vascular events | |
| Ponatinib | Hypertension |
| Vascular events |
Vascular events include coronary, cerebral, and peripheral events. CML, chronic myeloid leukemia; CV, cardiovascular; TKI, tyrosine kinase inhibitor. +/−Conclusive data are lacking.